QCG
PVLA

Quadrant Capital Group’s Palvella Therapeutics PVLA Stock Holding History

Quadrant Capital Group’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.25K Hold
10
– – ﹤0.01% 2561
2025
Q4 		$1.05K Hold
10
– – ﹤0.01% 2594
2025
Q3 		$627 Buy
+10
New +$446 ﹤0.01% 2592

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Quadrant Capital Group's PVLA Position: Q1 2026 in Review

Quadrant Capital Group held its Palvella Therapeutics (PVLA) position steady in Q1 2026 at 10 shares worth $1.25K. The position accounts for ﹤0.01% of the portfolio, ranked #2561.

Quadrant Capital Group first reported a position in PVLA in Q3 2025 and has held it in 3 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Quadrant Capital Group held 10 shares of Palvella Therapeutics worth $1.25K as of Q1 2026.
  • Quadrant Capital Group left its Palvella Therapeutics share count unchanged in Q1 2026.
  • Palvella Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2561 holding.
  • Quadrant Capital Group first reported a position in Palvella Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.